AIM Vaccine Co (HKSE:06660) FCF Margin % : -16.56% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is AIM Vaccine Co FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. AIM Vaccine Co's Free Cash Flow for the six months ended in Dec. 2023 was HK$-117 Mil. AIM Vaccine Co's Revenue for the six months ended in Dec. 2023 was HK$708 Mil. Therefore, AIM Vaccine Co's FCF Margin % for the quarter that ended in Dec. 2023 was -16.56%.

As of today, AIM Vaccine Co's current FCF Yield % is -5.72%.

The historical rank and industry rank for AIM Vaccine Co's FCF Margin % or its related term are showing as below:

HKSE:06660' s FCF Margin % Range Over the Past 10 Years
Min: -76.5 Med: -39.34 Max: -2.01
Current: -39.34

During the past 5 years, the highest FCF Margin % of AIM Vaccine Co was -2.01%. The lowest was -76.50%. And the median was -39.34%.

HKSE:06660's FCF Margin % is ranked better than
63.73% of 1045 companies
in the Biotechnology industry
Industry Median: -143.92 vs HKSE:06660: -39.34

AIM Vaccine Co FCF Margin % Historical Data

The historical data trend for AIM Vaccine Co's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM Vaccine Co FCF Margin % Chart

AIM Vaccine Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

-2.01

-25.44

-66.77

-76.50

-39.34

AIM Vaccine Co Semi-Annual Data
	Dec19	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial			-	-89.77	-64.82	-66.60	-16.56

Competitive Comparison of AIM Vaccine Co's FCF Margin %

For the Biotechnology subindustry, AIM Vaccine Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AIM Vaccine Co's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM Vaccine Co's FCF Margin % distribution charts can be found below:

* The bar in red indicates where AIM Vaccine Co's FCF Margin % falls into.

AIM Vaccine Co FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

AIM Vaccine Co's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-510.952	/	1298.827
	=	-39.34 %

AIM Vaccine Co's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-117.215	/	707.673
	=	-16.56 %

AIM Vaccine Co FCF Margin % Related Terms

Thank you for viewing the detailed overview of AIM Vaccine Co's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

AIM Vaccine Co (HKSE:06660) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM Vaccine Co Ltd (HKSE:06660) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

91 Jianguo Road, 25th Floor, Building A, Chaoyang, Beijing, CHN

Website

https://www.aimbio.com

AIM Vaccine Co Ltd is a top full-chain vaccine corporation in China with businesses covering the whole industrial chain ranging from research and development, manufacturing and commercialization. The products available for sale mainly include Recombinant HBV vaccine, Human rabies vaccine, HFRS Vaccine, hepatitis A vaccine (human diploid cell), Group A, C, Y and W135 MPSV, mumps vaccine, freeze-dried human rabies vaccine (Vero cell) and ACYW135 meningococcal polysaccharide vaccine. Geographically, the company generates all of its revenues in the PRC.

Executives

Zhao Yin Jin Rong Kong Gu Shen Zhen You Xian Gong Si	2201 Interest of corporation controlled by you
Zhao Shang Yin Xing Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong You Xian Gong Si	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Zi Ben Guan Li Shen Zhen You Xian Gong Si	2201 Interest of corporation controlled by you
Ning Bo Shi Bei Lun Qu Guo You Zi Ben Yun Ying You Xian Gong Si	2201 Interest of corporation controlled by you
Ning Bo Bao Shui Qu Kong Gu You Xian Gong Si	2101 Beneficial owner
Yong Zhou Qing Teng Mao Yi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Li Lihua	2201 Interest of corporation controlled by you
Shang Hai Xun Jing Qi Ye Guan Li Zhong Xin You Xian He Huo	2201 Interest of corporation controlled by you
Zhu Hai Tong Dao Ming Tian Tou Zi He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Mei Hua Sheng Wu Ke Ji Ji Tuan Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
La Sa Mei Hua Sheng Wu Tou Zi Kong Gu You Xian Gong Si	2101 Beneficial owner
Xi Zang Dong Fang Zhi Hui Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Shen Yang Qian Qian Qi Ye Guan Li Zi Xun You Xian Gong Si	2101 Beneficial owner

AIM Vaccine Co (HKSE:06660) Headlines

No Headlines